AstraZeneca: new diabetes device approved in Europe
(CercleFinance.com) - AstraZeneca said on Thursday that European regulators had given the green light to its new device for patients with type-2 diabetes, known as "Bydureon BCise.
"
The drugmaker today announced that the European Commission has approved the suspension for injection in pre-filled pen as a new formulation within the marketing authorisation for Bydureon.
The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled pen device that requires no titration that helps improve glycaemic control in adults with type-2 diabetes.
The formulation had already been approved by the US Food and Drug Administration in October 2017.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
"
The drugmaker today announced that the European Commission has approved the suspension for injection in pre-filled pen as a new formulation within the marketing authorisation for Bydureon.
The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled pen device that requires no titration that helps improve glycaemic control in adults with type-2 diabetes.
The formulation had already been approved by the US Food and Drug Administration in October 2017.
Copyright (c) 2018 CercleFinance.com. All rights reserved.